Table 1. Distribution of SCC and HSIL cases by region and study characteristics.
| Lesion | No. of studies | No. of cases | Source region (% of cases) | Cervical specimen for HPV testing (% of cases) | PCR primers used (% of cases) |
|---|---|---|---|---|---|
| SCC | 78 | 8594 | Africa (6.9), Asia (31.7), | Broad spectruma (61.9) | |
| Europe (32.0), North America/Australia | Biopsies (83.4) | Narrow spectrumb (15.5) | |||
| (13.0), South/Central America (16.5) | Exfoliated cells (16.6) | Combination/other (16.3) | |||
| Type-specific only (6.4) | |||||
| Broad spectruma (80.8) | |||||
| HSIL | 53 | 4338 | Africa (1.8), Asia (16.7), Europe | Biopsies (34.1) | Narrow spectrumb (7.9) |
| (52.4), North America (10.3), | Exfoliated cells (65.9) | Combination/other (7.4) | |||
| South/Central America (18.8) | Type-specific only (3.9) |
HPV=human papillomavirus; SCC=squamous cell/unspecified carcinoma of the cervix; HSIL=high-grade squamous intraepithelial lesion; PCR=polymerase chain reaction;
a
‘Broad’-spectrum PCR primers include MY09/11, GP5+/6+ and SPF10.
b
‘Narrow’-spectrum PCR primers include GP5/6, L1C1/C2 and PU1M/2R.